Michael Gelband’s Monte Rosa Therapeutics GLUE Stock Holding History

Michael Gelband’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.93M	Buy	+121,121	New	+$2.29M	0.02%	669
2025 Q3	–	Sell	-109,227	Closed	-$493K	–	1719
2025 Q2	$493K	Buy	109,227 +12,882	+13%	+$57.5K	﹤0.01%	1157
2025 Q1	$447K	Buy	+96,345	New	+$591K	﹤0.01%	1131
2024 Q4	–	Sell	-393,586	Closed	-$2.09M	–	1706
2024 Q3	$2.09M	Buy	393,586 +86,267	+28%	+$435K	0.01%	721
2024 Q2	$1.15M	Buy	307,319 +42,041	+16%	+$214K	0.01%	974
2024 Q1	$1.87M	Buy	265,278 +35,474	+15%	+$210K	0.01%	734
2023 Q4	$1.3M	Sell	229,804 -389,444	-63%	-$1.53M	0.01%	723
2023 Q3	$2.97M	Sell	619,248 -50,247	-8%	-$323K	0.03%	541
2023 Q2	$4.59M	Buy	669,495 +407,902	+156%	+$2.64M	0.04%	478
2023 Q1	$2.04M	Buy	+261,593	New	+$1.82M	0.02%	869

Other funds holding GLUE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Michael Gelband's GLUE Position: Q2 2026 in Review

Michael Gelband opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 121,121 shares worth $2.93M. The stake represents 0.02% of the portfolio and ranks #669 among its holdings. This is a return to the name: Michael Gelband previously reported a position in GLUE as recently as Q2 2025.

Michael Gelband first reported a position in GLUE in Q1 2023 and has held it in 10 quarters since. The position peaked at $4.59M in Q2 2023. 191 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

Michael Gelband held 121,121 shares of Monte Rosa Therapeutics worth $2.93M as of Q2 2026.
Monte Rosa Therapeutics was a new Michael Gelband position in Q2 2026.
Monte Rosa Therapeutics made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #669 holding.
Michael Gelband first reported a position in Monte Rosa Therapeutics in Q1 2023 and has held it in 10 quarters since.
Michael Gelband's Monte Rosa Therapeutics position peaked at $4.59M in Q2 2023.
191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.